TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Axillary Lymph Node Tattoo Marking Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Any patient presenting with a new diagnosis of breast cancer or with imaging findings highly suspicious for breast cancer (BI-RADS® 4C and 5) and suspicious axillary lymph node(s) is potentially eligible. Inclusion criteria are those eligible patients who have axillary lymph node(s) that are suspicious by imaging. Evaluation of the axilla with US will be performed when clinically warranted, with lymph node sampling recommended by the radiologist based on morphologically abnormal features.~* Age 18 years. Because no dosing or adverse event data are currently available on the use of Spot™ ink in participants \<18 years of age, children are excluded from this study.~Patients must be able to undergo breast imaging and surgical procedures, and therefore have a ECOG performance status ≤2 (Karnofsky ≥60%).~* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.~* Women who are pregnant or lactating are eligible as Spot™ ink is placed focally in the axillary lymph node and breast tissues.~* Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~Exclusion criteria includes patients who have upper body or ipsilateral arm tattoos, as that ink may already be present in regional nodes and may confound visibility of Spot™ ink \[19\]. If NAC has already been initiated and the lymph node is no longer visualized, tattooing will not be performed, and that patient will also be excluded.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to Spot™ ink.~* Participants with uncontrolled intercurrent illness.~* Participants with psychiatric illness/social situations that would limit compliance with study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lymph Node SpotTM Tattoo (Type: EXPERIMENTAL): Spot™ ink tattooing will be administered once prior to surgery.~Initial test set of participants with previous sampled lymph nodes positive for metastasis will have SpotTM ink administered at time of standard of care pre-surgery radioseed localization.~A feasibility set of participants will have SpotTM ink administered at time standard of care lymph nodes sampling.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Idiopathic Anemia of Aging (IAA)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 70 years of age or older~* Diagnosed with anemia~* Hemoglobin level less than or equal to 11~* Able to perform most activities of daily living without restriction~Exclusion Criteria:~* History of serious heart, liver or kidney disease~* Cancer treated within the last year except for skin cancer (excluding melanoma)~* Problems with your immune system~* Received Epoetin Alfa within the last year

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-90 years old~* Primary unilateral VATS or major abdominal surgery~* BMI 20-36, weight ≥ 50kg~* Male and Female~* All races~Exclusion Criteria:~* Patient refusal~* Inpatient status at the time of surgery~* ASA class 4 or greater~* Pregnancy~* Non-English speaking or inability to participate in the study~* Patients with coagulopathy or on therapeutic anticoagulation~* Chronic steroid use~* Opioid use disorder~* Contraindication to performing any of the proposed blocks - active infection at the block site, systemic infection, allergy to local anesthetic medications~* Patients undergoing second surgery or urgent/emergent surgery~* Patients weighing \< 50kg~* History of chronic pain and/or opioid tolerant~* Anticipated requirement for patient-controlled analgesia (PCA)~* Allergy or intolerance to any medication specified in the study protocol or postoperative pain management regimen~* Liver disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Continuous nerve blocks (Type: ACTIVE_COMPARATOR): A total of 30 subjects equally distributed to either continuous Erector Spinae Plane block for unilateral thoracic surgery , or continuous Quadratus Lumborum block for major abdominal surgery. Patients in this group will receive 20ml 0.5% ropivacaine per block performed after positioning of the needle followed by continuous perineural infusion of 0.25% lidocaine (10ml/hr) beginning in the post-anesthesia care unit (PACU) and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.
- Single nerve blocks plus IV lidocaine infusion (Type: EXPERIMENTAL): A total of 30 subjects equally distributed to either Erector Spinae Plane block for unilateral thoracic surgery, or Quadratus Lumborum block for major abdominal surgery, will be included . Patients in this group will receive 20ml 0.5% ropivacaine, 4mg dexamethasone, and 20mcg dexmedetomidine (30mcg if only one block is performed) per block after proper positioning of the Tuohy needle. Upon patient arrival in the recovery room a continuous infusion of IV lidocaine 50 mg /hr will be started and continued for 72 hours or until 12 hours prior to patient discharge, whichever comes first, which is standard of care at this institution.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Focused Ultrasound for the Treatment of Pancreatic Cancer - an International Registry

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed and dated informed consent form~* Stated willingness to comply with all registry procedures and availability for the duration of the registry~* Histology proven pancreatic carcinoma in any area of pancreas~* Pancreatic tumor that can be treated by FUS~* Willingness and ability to complete follow-up interviews~Exclusion Criteria:~* Any disease, condition or surgery which would result in a contraindication to undergoing FUS therapy.~* Clinical trials of pancreatic cancer not of focused ultrasound or related activities~* Other non-pancreatic cancer clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pancreatic Cancer Participants (Type: None): No intervention will be administered. Assessments are performed as standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 85 years of age~* History of a remote MI (≥1 month)~* Survival of a ventricular arrhythmic event (VT/VF) that would mandate placement of an implantable cardioverter-defibrillator (ICD) (Patients who experience a ventricular arrhythmic event (VT/VF) while already being treated with Amiodarone (100-200 mg/day) are not excluded from the study. This is permitted provided that the patient had been treated with Amiodarone for at least 2 months prior to experiencing the index VT/VF event. These patients are randomized to either a higher dose of Amiodarone (e.g., 100mg/day -\> 200mg/day or 200mg/day -\> 400mg/day) or a higher dose of Amiodarone plus catheter ablation.)~* Patient cannot afford an ICD and thus has been planned for treatment with Amiodarone (or an increased dose of Amiodarone)~* Ability to understand the requirements of the study~* Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements~Exclusion Criteria:~* Patients with NYHA class IV congestive heart failure~* Prior ablation for a ventricular arrhythmia~* Presence of an LV thrombus~* Contraindication to anticoagulation~* Inability to access the endocardium because of mechanical mitral and aortic valve~* Life expectance \<1 year for any medical condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Amiodarone only (Type: ACTIVE_COMPARATOR): The control group will receive amiodarone only.
- Amiodarone + Catheter Ablation (Type: EXPERIMENTAL): The experimental group will receive amiodarone plus catheter VT ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HeartPhone Cancer Survivors Trial 2019

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Diagnosis of breast cancer, leukemia, or lymphoma \<15 yrs~* Completed chemotherapy with cardiotoxic anthracycline-based agents 1+ year ago~* English-proficiency~* Own \& use smartphone with Android operating system~Main Study and Ancillary Study Exclusion Criteria:~* Currently receiving curative treatment for cancer~* 90+ min/week moderate (or greater) intensity PA~* Any medical contraindications on the Physical Activity Readiness Questionnaire~* Require an assistive device for mobility or has any other condition that may limit or prevent participation in moderate-intensity physical activity~* Current smoker~* Pregnant or planning to become pregnant in the next 6 mos/breastfeeding~* Allergy to test substances~* Allergy to latex~Ancillary Study:~* Taking metformin~* Current medications that could conceivably alter the cardiovascular or thermoregulatory control or responses (e.g. beta blockers, calcium channel blockers, angiotensin receptor blockers)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- HeartPhone Intervention (Type: EXPERIMENTAL): Participants install the HeartPhone app on their smartphone. This app presents an image on a splash screen every time they activate their device. The image is randomly drawn from an image bank in the app. Repeated exposure to the image is designed to condition a more favorable automatic affective evaluation of physical activity and lead to increased physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 28mm Ceramic-on-Ceramic Total Hip Replacement Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who were previously enrolled in the COC28 IDE study, or~* Newly recruited individuals who are qualified based on the approved labeling of the device, and;~* Individuals who are willing and able to provide informed patient consent for participation in the study;~* Individuals who are willing and able to return for follow-up as specified by the study protocol; and~* Individuals who are willing and able to complete the Hip Outcomes questionnaire and SF-12 Health Survey as specified by the study protocol~Exclusion Criteria:~* In the opinion of the Investigator, the individual does not qualify based upon approved labeling requirements.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ceramax COC 28mm Acetabular Cup (Type: None): The 28 mm ceramic acetabular bearing insert component is manufactured from high purity, dense alumina matrix composite ceramic. The inserts secure to DePuy's Pinnacle acetabular shells by means of an interlocking mechanical taper. The Pinnacle acetabular shell is a hemispherical type acetabulum replacement prosthesis, is available in a range of outer diameter (OD) sizes, and is used with a 28mm femoral head. Pinnacle 100 shells will be used in this study. The BIOLOX® delta ceramic femoral head components are manufactured from the same ceramic material as the acetabular bearing insert components. The femoral head is secured to the femoral stem component with an interlocking taper.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient who is at least 18 years old~* ASA physical class I or II~* BMI \<40 kg/m2,~* Presents for elective cervical cerclage during their first or second trimester of pregnancy will be eligible to participate.~Exclusion Criteria:~* Any patient who is not a candidate for neuraxial anesthesia (including coagulopathy,~* Local skin infection, uncorrected hypovolemia)~* Allergy to lidocaine or fentanyl~* Chronic opioid user~* History of failed neuraxial anesthesia or analgesia,~* Had prior spine surgery~* Can not assume a sitting position for spinal anesthesia due to risk of amniotic membrane rupture

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spinal Lidocaine Administration (Type: EXPERIMENTAL): Spinal anesthesia will be induced with isobaric 2% lidocaine and 15 μg fentanyl.~The study lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). If the lidocaine dose provides an unsatisfactory anesthetic, the case will be categorized as a failure. After a failed case, the next participant will receive a lidocaine dose increased by 4 mg. If the lidocaine dose provides satisfactory anesthesia, the next participant's lidocaine dose will determined by a biased allocation method with a 90% chance of maintaining the dose and a 10% chance of decreasing the dose by 4 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intraocular Pressure in Ocular Hypertensives With Scleral Lens Wear

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ocular hypertension (IOP \>22 in each eye during at least two visits over the previous 3 years)~* May have had cataract extraction and intraocular lens (IOL)~* Not on topical medication for glaucoma~* No History of ALT/SLT~* Any Age, 18 years or older~* History of contact lens wear (except scleral lenses), as long as they are willing to not wear their lenses the day of the study~Exclusion Criteria:~* On topical medication for glaucoma~* Eye disease~* Inability to wear scleral lenses~* Any intraocular surgery other than uncomplicated cataract extraction.~* Known allergy to proparacaine eye drops

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Eye (Type: EXPERIMENTAL): One eye will be randomly selected to wear the scleral lenses to be worn during study measurements
- Control Eye (Type: NO_INTERVENTION): Non-lens wearing eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prehabilitation for Elective Major Abdominal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Elective major abdominal surgery:~* Esophagus, stomach~* Liver, pancreas~* Small intestine, colon, rectum~* Benign or malignant disease~* Other intra-abdominal open or laparoscopic surgery lasting\> 2 hours~* Delay of 3 weeks between consultation and surgery~Exclusion Criteria:~* Patient \< 18 years, consent not obtained~* Coronary artery disease (≥ stage III according to CCS)~* Heart disease (≥ stage III according to NYHA)~* Uncontrolled cardiac arrhythmias~* COPD (GOLD stage ≥ III)~* Physical inability to ride a bike~* Orthopedic surgery in the last 6 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Prehabilitation (Type: EXPERIMENTAL): The patients will undergo an exercise test on a cycle ergometer (VO2 max), a grip strength test (Jamar dynamometer), a Time Up and Go (TUG) test and a 6 Minutes Walking Test (6-MWT), before and after prehabilitation. Intervention involves 3 training sessions per week during 3 weeks preoperatively, according to the high intensity interval training model, wich consists of:~* 5 minute warm-up (50% of Cardiopulmonary exercise testing, CPET)~* Two 10 minute series of 15 sec sprint intervals (100%) interspersed by 15 sec pauses and a 4 min rest between the two series~* Cool down with a 5 min active recovery period (30%) The grip strength test (Jamar dynamometer), TUG-test and 6-MWT will be repeated between 4 and 6 weeks and 8 and 10 week postoperatively.
- Controls (Type: NO_INTERVENTION): The patients will also undergo an exercise test on a cycle ergometer, a grip strength test (Jamar dynamometer), a TUG-test and a 6-MWT, but only once preoperatively, and between 4 and 6 weeks and 8 and 10 week postoperatively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of NMS-1116354 in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Advanced/metastatic solid tumors, for which no alternative effective standard therapy is available~2. Maximum of 4 regimens of prior cancer therapy allowed~3. Prior radiotherapy allowed if no more than 25% of BM reserve irradiated~4. Resolution of all acute toxic effects (excluding alopecia) of any prior anticancer therapy~5. ECOG performance status (PS) 0 or 1~6. Adult (age \>/= 18 and \</= 80 years) patients~7. Adequate renal, liver and BM reserve~8. Capability to swallow capsules intact~Exclusion Criteria:~1. Current enrollment in another therapeutic clinical trial~2. Known brain metastases~3. Currently active second malignancy~4. Major surgery within 4 weeks prior to treatment~5. Any of the following in the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~6. Pregnancy or breast-feeding women~7. Known active infections~8. Gastrointestinal disease or other malabsorption syndromes that would impact on drug absorption~9. Adrenal insufficiency~10. Other severe acute or chronic medical or psychiatric condition that could compromise protocol objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open-angle glaucoma without pseudoexfoliation or pigment dispersion component;~* Either two or more years of dosing with Travatan, or no prior exposure (less than 1 month) to a topical ocular prostaglandin;~* Requires a trabeculectomy;~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Pseudoexfoliation or pigment dispersion;~* History of chronic or recurrent severe inflammatory eye disease;~* History of or current ocular infection or ocular inflammation within the past 3 months in either eye;~* Greater than one month but less than two years of exposure to TRAVATAN;~* Pregnant, breast-feeding, not using highly effective birth control;~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TRAVATAN (Type: None): As prescribed by physician for the treatment of open-angle glaucoma and dosed for at least two years
- Treatment Naive (Type: None): No prior exposure (or less than 1 month) to any topical, ocular prostaglandin analogue

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy